| scholarly article | Q13442814 |
| P2093 | author name string | Inchauspé G | |
| Trépo C | |||
| Karayiannis P | |||
| Depla E | |||
| Maertens G | |||
| Fournillier A | |||
| Vidalin O | |||
| P2860 | cites work | DNA sequencing with chain-terminating inhibitors | Q22066207 |
| Optimal induction of hepatitis C virus envelope-specific immunity by bicistronic plasmid DNA inoculation with the granulocyte-macrophage colony-stimulating factor gene. | Q27469577 | ||
| Occurrence of antibodies reactive with more than one variant of the putative envelope glycoprotein (gp70) hypervariable region 1 in viremic hepatitis C virus-infected patients | Q27480288 | ||
| DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid | Q27480298 | ||
| Hepatitis C virus glycoprotein folding: disulfide bond formation and association with calnexin | Q27480329 | ||
| Formation of native hepatitis C virus glycoprotein complexes. | Q27480776 | ||
| Epitope mapping of antibodies directed against hypervariable region 1 in acute self-limiting and chronic infections due to hepatitis C virus | Q27480822 | ||
| Immunization with plasmid DNA encoding hepatitis C virus envelope E2 antigenic domains induces antibodies whose immune reactivity is linked to the injection mode | Q27480864 | ||
| Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses | Q27485996 | ||
| Expression and identification of hepatitis C virus polyprotein cleavage products | Q27486022 | ||
| Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses | Q27486074 | ||
| Expression of processed envelope protein of hepatitis C virus in mammalian and insect cells | Q27486219 | ||
| Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein | Q27487933 | ||
| Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome | Q27860719 | ||
| An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis | Q27860909 | ||
| Hepatitis C virus infection is associated with the development of hepatocellular carcinoma | Q28131791 | ||
| Protein folding in the cell | Q29547792 | ||
| A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells | Q29615897 | ||
| Vaccination of chimpanzees against infection by the hepatitis C virus | Q29615899 | ||
| Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses | Q35793550 | ||
| Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein. | Q35854300 | ||
| Gene inoculation generates immune responses against human immunodeficiency virus type 1 | Q36284135 | ||
| Sequence variation in hepatitis C viral isolates. | Q36472670 | ||
| Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. | Q36633402 | ||
| DNA immunization: induction of higher avidity antibody and effect of route on T cell cytotoxicity. | Q36828240 | ||
| Therapy of Hepatitis C | Q40435919 | ||
| Molecular chaperones in protein folding: the art of avoiding sticky situations | Q40621904 | ||
| Continuous human cell lines inducibly expressing hepatitis C virus structural and nonstructural proteins | Q41027365 | ||
| Characterization of truncated forms of hepatitis C virus glycoproteins. | Q41091382 | ||
| Complex processing and protein:protein interactions in the E2:NS2 region of HCV. | Q41436960 | ||
| Gene vaccination: plasmid DNA is more than just a blueprint | Q41724485 | ||
| A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures | Q42978625 | ||
| Plasmid DNA expressing a secreted or a nonsecreted form of hepatitis C virus nucleocapsid: comparative studies of antibody and T-helper responses following genetic immunization | Q42981690 | ||
| Modulation of immune responses to hepatitis C virus envelope E2 protein following injection of plasmid DNA using single or combined delivery routes | Q42988946 | ||
| Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties | Q42990001 | ||
| High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. | Q42990186 | ||
| Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment | Q43036993 | ||
| Processing of the E1 glycoprotein of hepatitis C virus expressed in mammalian cells | Q43046660 | ||
| Heterologous protection against influenza by injection of DNA encoding a viral protein | Q43828996 | ||
| Direct gene transfer into mouse muscle in vivo | Q44656494 | ||
| Immune-mediated destruction of transfected muscle fibers after direct gene transfer with antigen-expressing plasmid DNA. | Q45881597 | ||
| Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. | Q52845358 | ||
| Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization | Q74184098 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| Hepatitis C virus | Q708693 | ||
| hepatitis C | Q154869 | ||
| virology | Q7215 | ||
| immunization | Q1415366 | ||
| P304 | page(s) | 7497-7504 | |
| P577 | publication date | 1999-09-01 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Expression of noncovalent hepatitis C virus envelope E1-E2 complexes is not required for the induction of antibodies with neutralizing properties following DNA immunization | |
| P478 | volume | 73 |
| Q36065682 | A candidate DNA vaccine elicits HCV specific humoral and cellular immune responses |
| Q29048140 | Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2. |
| Q81319818 | Characterization of the immune response to DNA vaccination strategies for schistosomiasis candidate antigen, Sm-p80 in the baboon |
| Q27488724 | Conserved peptides within the E2 region of Hepatitis C virus induce humoral and cellular responses in goats |
| Q34552781 | Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response |
| Q36308565 | DNA immunization with fusion genes encoding different regions of hepatitis C virus E2 fused to the gene for hepatitis B surface antigen elicits immune responses to both HCV and HBV |
| Q35105726 | Development of a hepatitis C virus vaccine |
| Q27469682 | Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates |
| Q27470000 | Genetic immunization of wild-type and hepatitis C virus transgenic mice reveals a hierarchy of cellular immune response and tolerance induction against hepatitis C virus structural proteins |
| Q57160237 | Hepatitis C vaccines |
| Q40166844 | Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies |
| Q40605284 | Immunogenicity of the E1E2 proteins of hepatitis C virus expressed by recombinant adenoviruses |
| Q34422723 | Immunoprophylaxis of hepatitis C virus infection. |
| Q39921190 | Murine neutralizing antibody response and toxicity to synthetic peptides derived from E1 and E2 proteins of hepatitis C virus |
| Q34979868 | The challenge of developing a vaccine against hepatitis C virus |
| Q40468610 | West Nile premembrane-envelope genetic vaccine encoded as a chimera containing the transmembrane and cytoplasmic domains of a lysosome-associated membrane protein: increased cellular concentration of the transgene product, targeting to the MHC II co |
| Q73549448 | [Molecular biology of hepatitis C virus: implications for the development of new therapies and prophylactic vaccine] |
Search more.